Needham & Company Maintains a 'Hold' on Ultra Clean (UCTT); Like AIT Acquisition, But Macro Headwinds Still Linger
Get Alerts UCTT Hot Sheet
Price: $84.93 -8.59%
Rating Summary:
9 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
9 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Ultra Clean (NASDAQ: UCTT).
Analyst, Y. Edwin Mok, said, "Long term, we like the AIT acquisition for several reasons: 1) increased scale and cost leverage; 2) immediate earnings accretion; 3) complementary customer base; 4) added new capabilities; and 5) furthering of efforts in non-semi markets. However, we believe softer near-term demand in the semicap sector will offset the earnings accretion from the acquisition, and as a result our 2012 earnings estimate remains unchanged despite higher total revenues."
FY13 EPS estimate raised from $0.82 to $0.93.
For an analyst ratings summary and ratings history on Ultra Clean click here. For more ratings news on Ultra Clean click here.
Shares of Ultra Clean closed at $6.55 yesterday.
Analyst, Y. Edwin Mok, said, "Long term, we like the AIT acquisition for several reasons: 1) increased scale and cost leverage; 2) immediate earnings accretion; 3) complementary customer base; 4) added new capabilities; and 5) furthering of efforts in non-semi markets. However, we believe softer near-term demand in the semicap sector will offset the earnings accretion from the acquisition, and as a result our 2012 earnings estimate remains unchanged despite higher total revenues."
FY13 EPS estimate raised from $0.82 to $0.93.
For an analyst ratings summary and ratings history on Ultra Clean click here. For more ratings news on Ultra Clean click here.
Shares of Ultra Clean closed at $6.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Vivos Therapeutics posts 35% revenue gain but widens net loss
- Coherent (COHR) PT Raised to $420 at Needham
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ChangeRelated Entities
Needham & Company, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share